Shares of Jeena Sikho Lifecare plunged more than 18% on Monday, November 16, after the Ayurveda-focused healthcare company reported a sharp decline in profitability for the September quarter of FY27. The stock touched a 21-month low of approximately ₹280 on the NSE as investors reacted to a significant increase in operating expenses and a contraction in operating margins.

The company reported consolidated revenue from operations of ₹235.13 crore, an increase of nearly 24% year-on-year. However, consolidated net profit attributable to the owners declined approximately 38% to ₹36.67 crore from ₹58.77 crore in the corresponding quarter last year. The earnings performance also weakened sequentially, with profit falling around 44% compared with the June quarter. The results raised concerns about whether the company’s rising expenditure is translating into sustainable earnings growth.

Jeena Sikho Lifecare Share Price Falls 18%

Jeena Sikho Lifecare shares came under heavy selling pressure following the quarterly earnings announcement.

The stock declined more than 18% during Monday’s trading session, touching approximately ₹280 per share on the NSE. This was its lowest level in around 21 months.

The decline extended the stock’s longer-term correction. Shares were already under pressure after falling substantially from their 52-week high of ₹809, recorded on February 9, 2026.

The stock has now lost more than 65% from that peak.

The sharp market reaction reflects concerns about the company’s profitability despite continued revenue growth. Investors are increasingly focusing on operating expenses, margins and the company’s ability to convert its expanding healthcare business into higher earnings.

Jeena Sikho Lifecare Q2 FY27 Results: Key Financial Highlights

The September-quarter results showed that revenue growth did not translate into higher profits.

Financial metricQ2 FY27Q2 FY26Year-on-year change
Revenue from operations₹235.13 crore₹189.85 crore+24%
EBITDA₹72.02 crore₹92.06 crore-22%
EBITDA margin31%48%Down 17 percentage points
Profit after tax₹36.34 crore*₹58.79 crore-38%
Basic EPS₹2.92₹4.73-38%

*The company’s investor presentation reports profit after tax of approximately ₹36.34 crore, while its consolidated financial statement reports ₹36.63 crore in total profit and ₹36.67 crore attributable to owners of the parent. Figures can differ because of reporting and attribution adjustments.

The most significant concern was the decline in operating profitability.

Although revenue increased by 24%, EBITDA declined 22% to approximately ₹72 crore. The EBITDA margin contracted to 31% from 48% in the year-ago quarter.

This indicates that the company retained a considerably smaller portion of its revenue as operating earnings.

Why Did Jeena Sikho Lifecare’s Profit Fall 38%?

The sharp decline in profitability was largely associated with a substantial increase in operating expenses.

According to the company’s investor presentation, operating expenses increased 83% year-on-year to approximately ₹135.17 crore in Q2 FY27, compared with ₹73.70 crore in the corresponding quarter last year.

The increase was considerably faster than the 24% growth in revenue.

Three expenditure categories contributed to the higher costs:

1. Higher advertising and promotional expenditure

Jeena Sikho increased advertising and promotional spending by approximately ₹13.4 crore.

The company said the additional expenditure was driven by strategic brand-building initiatives aimed at expanding its reach among younger consumers, particularly Generation Z.

The initiatives included campaigns featuring Acharya Manish Grover on popular television platforms.

The company is investing in brand recognition and customer acquisition, but the additional spending has increased near-term pressure on profitability.

2. Higher employee expenses

Employee benefit expenses increased by approximately ₹4.1 crore.

The company attributed this to additional manpower, recruitment of new talent ahead of planned expansion into new markets and performance-linked salary revisions.

As Jeena Sikho expands its healthcare network, employee costs could remain an important component of its operating expenditure.

3. Higher expected credit loss provisions

The company also reported an increase of approximately ₹2.5 crore in expected credit loss provisions.

It attributed the higher provision to a cautious approach based on recent collection experience and settlement patterns involving government customers.

These expenses contributed to the overall increase in operating costs and weakened the company’s operating margins.

Sequential Profit Decline Adds to Investor Concerns

The company’s performance also weakened compared with the preceding June quarter.

Revenue from operations increased approximately 5% sequentially, from ₹224.40 crore in Q1 FY27 to ₹235.13 crore in Q2 FY27.

However, EBITDA declined 22% quarter-on-quarter, while profit after tax fell approximately 45%.

Financial metricQ1 FY27Q2 FY27Sequential change
Revenue₹224.40 crore₹235.13 crore+5%
EBITDA₹92.12 crore₹72.02 crore-22%
Profit after tax₹65.69 crore₹36.34 crore-45%
EBITDA margin41%31%Down 10 percentage points

The sequential decline highlights that the profitability pressure was not limited to comparisons with the previous financial year.

While the company continued to generate higher revenue, its operating costs and lower other income affected the final earnings figure.

Jeena Sikho Lifecare’s Expansion Strategy and Business Model

Jeena Sikho Lifecare operates in the Ayurveda healthcare segment, offering treatments and services through hospitals, clinics, day-care facilities and related healthcare products.

Its business includes traditional Ayurvedic treatment programmes, Panchakarma services, inpatient care and outpatient consultations.

The company has been expanding its healthcare network and investing in brand-building to attract a larger customer base.

Its growth strategy involves increasing treatment capacity, expanding into new markets and strengthening its position in India’s organised Ayurveda healthcare industry.

However, expansion also brings additional costs, including employee recruitment, marketing, infrastructure and operational expenditure.

The latest results illustrate the financial challenge of scaling a healthcare business while maintaining profitability.

For investors, the key question is whether the additional spending will eventually generate higher patient volumes, improved revenue per facility and stronger operating margins.

What Should Investors Watch After the Q2 Results?

The latest earnings announcement puts several business indicators under scrutiny.

Operating margins: Investors will monitor whether the EBITDA margin can recover from 31% as the company manages its operating costs.

Advertising returns: Higher promotional spending will need to translate into improved brand recognition, customer acquisition and revenue growth.

Employee costs: Expansion-related recruitment could continue increasing expenses, making productivity and utilisation important factors.

Government receivables: The increase in expected credit loss provisions highlights the importance of monitoring collection cycles and payments from government customers.

Revenue growth: The company will need to maintain its expansion momentum while ensuring that additional revenue contributes meaningfully to operating profit.

These indicators will help determine whether the latest decline in profitability is temporary or reflects more persistent pressure on the business model.

The Bigger Picture

Jeena Sikho Lifecare’s latest results highlight a common challenge for expanding healthcare companies: growing revenue does not necessarily translate into growing profits. The company delivered 24% revenue growth, but its operating expenses increased much faster, leading to a 22% decline in EBITDA and a sharp contraction in margins.

The company’s investment in advertising, recruitment and expansion could support future business growth, but the returns on those investments remain important. The stock’s steep correction indicates that investors are reassessing the relationship between growth, expenditure and profitability. A sustained recovery will depend on the company’s ability to convert its expanding operations into stronger earnings and cash generation.

Looking Ahead

The coming quarters will be important for determining whether Jeena Sikho’s higher marketing and employee expenditure delivers the expected business benefits. Investors will watch patient volumes, revenue growth, operating margins and collection efficiency for signs of improvement. A recovery in profitability alongside continued revenue expansion could help address concerns raised by the September-quarter results.

For the stock, the immediate focus is likely to remain on earnings visibility and the company’s ability to control costs. The decline of more than 65% from its 52-week high reflects a significant change in market sentiment, but the next direction will depend on future financial performance rather than the share-price correction alone. The company will need to demonstrate that its expansion strategy can generate sustainable returns.

Get the day’s top stories in your inbox

One concise email. No spam, unsubscribe anytime.